The systemic hormonal preparations market in the UK, excluding sex hormones and insulins, was valued at 641 million USD in 2024. This market shows a declining trend with values forecasted to reach 637.6 million USD by 2028. The year-on-year percentage decrease in the market size is about 0.14%, indicating a gradual but consistent decline. Analysis over the last two years reveals a sustained downward movement, and the compounded annual growth rate (CAGR) over the forecast period demonstrates a continual reduction in growth at a moderate pace.
Future trends to watch in this market may include advancements in alternative therapies, regulatory changes, or shifting preferences in clinical practice, potentially impacting the sales of systemic hormonal preparations. Additionally, innovations in related healthcare sectors could either compound or counterbalance this declining trend.
